Nash

Breakthrough for liver disease patients with ascites that could eliminate needle paracentesis

22-Jun-2023 By Liza Laws

Sequana Medical has just announced additional data on safety, quality of life and survival from its North American alfapump study, called Poseidon which could signal an end to manual draining of ascites.

CN Bio launches single-organ throughput system with multiple liver plates

28-Feb-2023 By Liza Laws

A single-organ higher throughput (HT) system has been launched by CN Bio's PhysioMimix range for the first time.

Owlstone Medical publishes data on biomarkers for liver disease detection

09-Feb-2023 By Liza Laws

A study has shown that the use of exhaled volatile organic compounds (VOCs) can be used as biomarkers for differentially identifying liver disease on breath.

Survey reveals patients’ thoughts on trial participation

25-Jan-2021 By Jenni Spinner

Conducted by SubjectWell, the survey of patients with Type 2 diabetes reveals how ethnicity and other factors play a part in trial participation tendencies.

Intercept activates contract sales force to support NASH drug launch

14-Nov-2019 By Nick Taylor

Intercept Pharmaceuticals prepares to introduce NASH drug onto the market by hiring a contract sales team.

Researchers create miniature livers to support NASH R&D

20-Aug-2019 By Nick Taylor

Researchers show miniature livers can develop steatohepatitis and fibrosis, pointing to potential for personalized hepatic drug discovery and toxicity platforms.

Clinical trials center joins ProSciento’s program for NASH trial recruitment

20-Jun-2019 By Maggie Lynch

High Point Clinical Trials Center is partnering with ProSciento to accelerate clinical trial recruitment of patients with NASH and NAFLD.

Gilead doubles down on NASH with two deals in one week

16-Apr-2019 By Ben Hargreaves

Gilead arranges partnerships with insitro and Novo Nordisk to develop new options for patients with NASH.

Novartis bets $1.6bn on inflammation-focused biotech

01-Apr-2019 By Ben Hargreaves

Novartis to acquire IFM Tre to gain access to one clinical and two pre-clinical assets, which are designed to combat chronic inflammatory conditions.